Journal of Family & Community Medicine
Home About us Editorial board Search Ahead of print Current issue Archives Submit article Instructions Subscribe Contact us Login 
 

Users Online: 487 Home Print this page Email this page Small font sizeDefault font sizeIncrease font size

 

 Table of Contents 
ORIGINAL ARTICLE
Year : 2020  |  Volume : 27  |  Issue : 2  |  Page : 109-113  

Cherry angioma: A case–control study


1 Department of Medicine, Division of Dermatology, College of Medicine, King Saud bin Abdulaziz University for Health Sciences, Riyadh, Saudi Arabia
2 Department of Medicine, Division of Dermatology, Ministry of National Guard Health Affairs, Riyadh, Saudi Arabia
3 National Center for Evidence Based Health Practice, Saudi Health Council, Riyadh, Saudi Arabia
4 Department of Medical Education, Research Unit, College of Medicine, King Saud bin Abdulaziz University for Health Sciences, Riyadh, Saudi Arabia
5 Department of Medicine, Division of Dermatology, College of Medicine, King Saud bin Abdulaziz University for Health Sciences; Department of Medicine, Division of Dermatology, Ministry of National Guard Health Affairs; Department of Medical Education, Research Unit, College of Medicine, King Saud bin Abdulaziz University for Health Sciences; King Abdullah International Medical Research Center, Riyadh, Saudi Arabia

Date of Submission10-Dec-2019
Date of Acceptance30-Mar-2020
Date of Web Publication03-Jun-2020

Correspondence Address:
Dr. Mohammed I AlJasser
Division of Dermatology, King Saud Bin Abdulaziz University for Health Sciences, P.O. Box 3660, Riyadh 11481
Saudi Arabia
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/jfcm.JFCM_293_19

Rights and Permissions
   Abstract 

BACKGROUND: Cherry angiomas (CAs) are very common asymptomatic vascular skin lesions. There are only a few studies on CAs in the literature and those assessing risk factors of CAs are scarce. The aim of our study was to determine risk factors for the development of CAs.
MATERIALS AND METHODS: A case–control study was conducted at a tertiary care center in Riyadh, Saudi Arabia. Patients underwent a full-body examination for CAs. Demographics and other data including medical history and medications were extracted from electronic medical records.
RESULTS: A total of three hundred patients were enrolled: one hundred cases with at least five CAs and two hundred controls without CAs. Bivariate analysis identified benign prostatic hyperplasia (odds ratio [OR]: = 2.591), malignancy (OR = 2.567), tamsulosin (OR = 3.171), and clopidogrel (OR = 0.321) as statistically significant associations. After multivariate logistic regression analysis, only tamsulosin (OR = 3.475, P = 0.009) and clopidogrel (OR = 0.281, P = 0.028) were found to be independent risk factors for CAs. Malignancies tended to be more associated with CAs, but this did not reach statistical significance (P = 0.07).
CONCLUSION: Tamsulosin is a possible risk factor for the development of CAs. Clopidogrel seems to have a protective role preventing the development of CAs.

Keywords: Campbell de Morgan spots, cherry angioma, cherry hemangioma, senile hemangioma


How to cite this article:
Nazer RI, Bashihab RH, Al-Madani WH, Omair AA, AlJasser MI. Cherry angioma: A case–control study. J Fam Community Med 2020;27:109-13

How to cite this URL:
Nazer RI, Bashihab RH, Al-Madani WH, Omair AA, AlJasser MI. Cherry angioma: A case–control study. J Fam Community Med [serial online] 2020 [cited 2020 Jul 12];27:109-13. Available from: http://www.jfcmonline.com/text.asp?2020/27/2/109/285817


   Introduction Top


Cherry angiomas (CAs) or “Campbell de Morgan spots” are one of the most common benign cutaneous vascular lesions. They present as asymptomatic, small, bright-red papules usually on the trunk and extremities of older individuals.[1] The frequency of CAs increases with age, but have no reported clinical consequences.[2] The incidence of CAs was 49.5% in males, who seem to be more commonly affected than females.[3] The treatment of CAs is cosmetic because they are benign and asymptomatic.[1]

The pathogenesis of CAs is not entirely known. Reduced expression of miR-424 in CAs was found to be associated with abnormal angiogenesis through MEK1 or cyclin E1.[4] Human herpesvirus 8 has a possible role in eruptive CAs.[5] Some somatic genetic mutations have been identified in CAs.[6]

Risk factors associated with the development of multiple CAs could include age, chronic immunosuppression, chronic graft-versus-host disease, and malignancy.[7],[8] Some studies suggest an association between CAs and the exposure to certain chemicals and drugs such as cyclosporine,[9] sulfur mustard,[10] nitrogen mustard,[11] and bromides.[12]

Studies on risk factors associated with CAs are few and limited mainly to case reports and uncontrolled studies. Controlled studies, which explored a limited number of variables, are surprisingly very few for this common condition. This study was done to explore risk factors associated with the occurrence of CAs.


   Materials and Methods Top


This was a case–control study conducted at King Abdulaziz Medical City, one of the largest tertiary care centers in Riyadh, Saudi Arabia. Ethical approval was obtained from the Institutional Review Board of King Abdullah International Medical Research Center and informed written consent was obtained from all participants.

Cases were defined as patients with five or more CAs. Controls were age- and gender-matched patients who did not have any CAs. Only Saudi patients aged ≥18 years and admitted to the hospital were included in the study. Patients who refused a full body examination, or had received previous treatment for CAs, or had 1–4 CAs were excluded from the study.

The target case-to-control ratio was 1:2. The sample size was estimated as hundred cases and two hundred controls using OpenEpi sample size calculator. The calculation was based on an estimated 30%–40% exposure to the risk factor in the control group, to detect an odds ratio (OR) of 2.0 or more at the 95% confidence level and power of 80%. A nonprobability consecutive sampling was used to select the cases, while the selection of controls was based on matching for age and gender.

Full-body skin examination was performed on all patients. Variables consisted of demographics, Fitzpatrick skin phototype, and region of residence. Furthermore, the duration of CA, body site, and diameter were documented. Data regarding family history, medical conditions, malignancies, and environmental triggers were collected. Details of current medications were gathered from the electronic medical record.

Statistical analysis was done using Statistical package for the Social Sciences (SPSS) version 24 (SPSS Inc., Chicago, IL, USA). Categorical variables were presented as frequencies and percentages and were compared using the Chi-square test. Numerical variables were reported as means with standard deviation and were compared by Student's t-test. Skewed numerical data were presented as median and inter-quartile range. Step-wise multivariate logistic regression analysis was performed to determine any associated risk factors, if any, for the development of CAs. Variables entered in the model were those with P < 0.2 between cases and controls in the bivariate analysis. The results of regression analysis were presented as OR with 95% confidence interval. For all the statistical tests, P < 0.05 was considered statistically significant.


   Results Top


A total of hundred cases and two hundred controls were enrolled in the study. The most common site of CAs was the trunk (mainly the chest) followed by the proximal extremities, head and neck, distal extremities, hands, and feet [Figure 1]. Similarly, the trunk had the highest number and CAs with the largest diameter [Table 1].
Figure 1: Distribution of cherry angiomas based on the body site (n = 100)

Click here to view
Table 1: Characteristics of cherry angiomas based on body site (n =100)

Click here to view


Patient characteristics are summarized in [Table 2]. No statistically significant difference was found between cases and controls with regard to age and gender. Similarly, no difference was found in body mass index, region of residence, job, and history of smoking. A family history of CA was positive in 12% of cases. The median duration of CAs was 6 years (interquartile range 3–20).
Table 2: Bivariate analysis of patient characteristics

Click here to view


Bivariate analysis identified benign prostatic hyperplasia (OR = 2.591), malignancy (OR = 2.567), tamsulosin (OR = 3.171), and clopidogrel (OR = 0.321) as statistically significant associations [Table 3]. After multivariate logistic regression analysis, only tamsulosin and clopidogrel were found to be independent risk factors for CAs [Table 4]. Patients on tamsulosin were more likely to have CAs (OR = 3.475, P = 0.009), while those on clopidogrel seem to be less likely to have CAs (OR = 0.281, P = 0.028). Malignancy tended to have more association with CAs, but this was not statistically significant (P = 0.07).
Table 3: Bivariate analysis: Factors associated with cherry angioma

Click here to view
Table 4: Multivariate logistic regression analysis: Factors associated with cherry angioma

Click here to view



   Discussion Top


Studies on CAs are generally limited. Trunk was the most common site affected with CAs in our cases, which is in agreement with the literature and clinical observation.[1] The pathogenesis of CAs is still poorly understood. Genetic factors could play a role in the development of CAs. Family history of CAs was found in 12% of our cases. Somatic mutations in GNAQ and GNA11 genes were recently identified in CAs.[6] These genes are also known to be involved in the pathogenesis of other cutaneous vascular conditions such as capillary malformations.

Controlled studies on the risk factors of CAs are scarce. Borghi et al. assessed the risk factors of eruptive CAs in a total of 1032 patients.[13] Those with eruptive CAs had ≥30 CAs. The comparative group had either no or <30 CAs. Age, immunosuppressive therapy, and malignancy were identified as independent risk factors for eruptive CAs. Malignancy in our study had a tendency of having statistically significant association with CAs., The number of CAs was significantly more on the skin of the affected breast in patients with unilateral breast cancer.[14] Serum lipids were shown to be more elevated in patients with CAs in a case–control study.[15] The lipid profile was not assessed in our study.

Tamsulosin and clopidogrel were identified in our study as independently significant associations with CAs. To the best of our knowledge, this association has not been previously reported. We found that patients on tamsulosin were more likely to have CAs. Tamsulosin is a selective alpha1A and alpha1D-adrenergic receptor blocker that is used in the treatment of BPH.[16] Alpha-1 adrenergic receptors are mainly found in the prostate and bladder. Tamsulosin works by relaxing smooth muscles in the prostate and bladder and therefore, improves urinary symptoms in patients with BPH. Although tamsulosin primarily works on the lower urinary tract, it has been shown to have some effect on the blood vessels, leading to vasodilation.[17] This might explain the association between tamsulosin and CAs found in our study.

Our findings indicate that clopidogrel seems to have a protective role against CA formation. Clopidogrel is an antiplatelet that prevents platelet aggregation through the inhibition of adenosine diphosphate.[18] It is used for the prevention of coronary artery disease and stroke. Clopidogrel has been recently shown to have an anti-angiogenic effect.[19] Both the number of microvessels and expression of vascular endothelial growth factor were significantly reduced by clopidogrel.

Our study has some limitations. Post hoc analysis showed the power of study as 60.45%, which could be due to the small sample size. The study was done at one center and therefore, its findings cannot be generalized. Another limitation is that our study design depended to some extent on patient recall of information. A better design would have been a prospective cohort but that would have been time-consuming and expensive.


   Conclusion Top


We identified tamsulosin as a possible risk factor for the development of CAs. However, clopidogrel seems to have a protective role, possibly preventing the development of CAs. Future well-designed studies are needed to confirm these findings.

Financial support and sponsorship

Nil.

Conflicts of interest

There are no conflicts of interest.



 
   References Top

1.
Higgins JC, Maher MH, Douglas MS. Diagnosing common benign skin tumors. Am Fam Physician 2015;92:601-7.  Back to cited text no. 1
    
2.
Luba MC, Bangs SA, Mohler AM, Stulberg DL. Common benign skin tumors. Am Fam Physician 2003;67:729-38.  Back to cited text no. 2
    
3.
Patange VS, Fernandez RJ. A study of geriatric dermatoses. Indian J Dermatol Venereol Leprol 1995;61:206-8.  Back to cited text no. 3
[PUBMED]  [Full text]  
4.
Nakashima T, Jinnin M, Etoh T, Fukushima S, Masuguchi S, Maruo K, et al. Down-regulation of mir-424 contributes to the abnormal angiogenesis via MEK1 and cyclin E1 in senile hemangioma: Its implications to therapy. PLoS One 2010;5:e14334.  Back to cited text no. 4
    
5.
Borghi A, Benedetti S, Corazza M, Gentili V, Ruina G, Di Luca D, et al. Detection of human herpesvirus 8 sequences in cutaneous cherry angiomas. Arch Dermatol Res 2013;305:659-64.  Back to cited text no. 5
    
6.
Klebanov N, Lin WM, Artomov M, Shaughnessy M, Njauw CN, Bloom R, et al. Use of targeted next-generation sequencing to identify activating hot spot mutations in cherry angiomas. JAMA Dermatol 2019;155:211-5.  Back to cited text no. 6
    
7.
Garnis S, Billick RC, Srolovitz H. Eruptive vascular tumors associated with chronic graft-versus-host disease. J Am Acad Dermatol 1984;10:918-21.  Back to cited text no. 7
    
8.
Borghi A, Minghetti S, Battaglia Y, Corazza M. Predisposing factors for eruptive cherry angiomas: New insights from an observational study. Int J Dermatol 2016;55:e598-600.  Back to cited text no. 8
    
9.
De Felipe I, Redondo P. Eruptive angiomas after treatment with cyclosporine in a patient with psoriasis. Arch Dermatol 1998;134:1487-8.  Back to cited text no. 9
    
10.
Firooz A, Komeili A, Dowlati Y. Eruptive melanocytic nevi and cherry angiomas secondary to exposure to sulfur mustard gas. J Am Acad Dermatol 1999;40:646-7.  Back to cited text no. 10
    
11.
Ma HJ, Zhao G, Shi F, Wang YX. Eruptive cherry angiomas associated with vitiligo: Provoked by topical nitrogen mustard? J Dermatol 2006;33:877-9.  Back to cited text no. 11
    
12.
Cohen AD, Cagnano E, Vardy DA. Cherry angiomas associated with exposure to bromides. Dermatology 2001;202:52-3.  Back to cited text no. 12
    
13.
Borghi A, Minghetti S, Battaglia Y, Corazza M. Predisposing factors for eruptive cherry angiomas: New insights from an observational study. Int J Dermatol 2016;55:e598-600.  Back to cited text no. 13
    
14.
Guastafierro A, Verdura V, Di Pace B, Faenza M, Rubino C. The influence of breast cancer on the distribution of cherry angiomas on the anterior thoracic wall: A case series study. Dermatology 2019;235:65-70.  Back to cited text no. 14
    
15.
Darjani A, Rafiei R, Shafaei S, Rafiei E, Eftekhari H, Alizade N, et al. Evaluation of lipid profile in patients with cherry angioma: A case-control study in Guilan, Iran. Dermatol Res Pract 2018;2018:4639248.  Back to cited text no. 15
    
16.
Dunn CJ, Matheson A, Faulds DM. Tamsulosin: A review of its pharmacology and therapeutic efficacy in the management of lower urinary tract symptoms. Drugs Aging 2002;19:135-61.  Back to cited text no. 16
    
17.
Harada K, Kawaguchi A, Ohmori M, Fujimura A. Antagonistic activity of tamsulosin against human vascular alpha1-adrenergic receptors. Clin Pharmacol Ther 2000;67:405-12.  Back to cited text no. 17
    
18.
Clopidogrel. Drugs and Lactation Database (LactMed) Bethesda (MD): National Library of Medicine (US); 2006  Back to cited text no. 18
    
19.
Luo JC, Peng YL, Chen TS, Huo TI, Hou MC, Huang HC, et al. Clopidogrel inhibits angiogenesis of gastric ulcer healing via downregulation of vascular endothelial growth factor receptor 2. J Formos Med Assoc 2016;115:764-72.  Back to cited text no. 19
    


    Figures

  [Figure 1]
 
 
    Tables

  [Table 1], [Table 2], [Table 3], [Table 4]



 

Top
 
 
  Search
 
    Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
    Access Statistics
    Email Alert *
    Add to My List *
* Registration required (free)  

 
  In this article
    Abstract
   Introduction
    Materials and Me...
   Results
   Discussion
   Conclusion
    References
    Article Figures
    Article Tables

 Article Access Statistics
    Viewed395    
    Printed71    
    Emailed0    
    PDF Downloaded73    
    Comments [Add]    

Recommend this journal

Advertise | Sitemap | What's New | Feedback | Disclaimer
Journal of Family and Community Medicine | Published by Wolters Kluwer - Medknow
Online since 05th September, 2010